Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Viveve Medical, Inc. (NASDAQ: VIVE).

Full DD Report for VIVE

You must become a subscriber to view this report.


Recent News from (NASDAQ: VIVE)

Viveve Appoints Two New Independent Board Members
ENGLEWOOD, Colo., Sept. 13, 2018 (GLOBE NEWSWIRE) -- Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women’s intimate health, today announced that Steve Basta and Karen Zaderej have joined the Viveve board of directors, effective today. “It is w...
Source: GlobeNewswire
Date: September, 13 2018 08:28
Viveve Submits Investigational Device Exemption to FDA to Conduct LIBERATE-U.S. Trial for Improvement of Stress Urinary Incontinence
ENGLEWOOD, Colo., Sept. 11, 2018 (GLOBE NEWSWIRE) -- Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women’s intimate health, today announced submission of an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) for author...
Source: GlobeNewswire
Date: September, 11 2018 08:28
Viveve to Present at 20th Annual Rodman & Renshaw Global Investment Conference
ENGLEWOOD, Colo., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Viveve Medical, Inc. ("Viveve") (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin, chief executive officer and director, will present at the 2018 Rodman & Renshaw Global ...
Source: GlobeNewswire
Date: August, 28 2018 08:28

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-143.253.453.453.14288,594
2017-03-104.124.204.204.126,760
2017-03-094.354.114.354.1016,675
2017-03-084.304.114.56734.0632,486
2017-03-074.184.194.36994.0631,294

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1312,97840,06932.3891Cover
2018-12-1231,734107,13129.6217Cover
2018-12-1122,34693,99223.7744Cover
2018-12-1058,969174,88733.7183Cover
2018-12-07346,887845,55541.0248Short

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on VIVE.


About Viveve Medical, Inc. (NASDAQ: VIVE)

Logo for Viveve Medical, Inc. (NASDAQ: VIVE)

Viveve Medical, Inc., is a women s health company passionately committed to advancing new solutions to improve women s overall well being and quality of life. The company s lead product, the globally patented Viveve System, is a non surgical, non ablative medical device that remodels collagen and restores tissue with only one treatment session. The Viveve System treats the condition of vaginal laxity that can result in decreased physical sensation and sexual satisfaction. Physician surveys indicate that vaginal laxity is the number one post delivery physical change for women, being more prevalent than weight gain, urinary incontinence or stretch marks. The Viveve Treatment uses patented, reverse thermal gradient radiofrequency technology to tighten vaginal tissue in one minute out patient treatment in a physician s office. The Viveve System has received regulatory approval in many countries throughout the world and is available through physician import license in Japan. It is currently not available for sale in the U.S. For more information, please visit Viveve s website at www.viveve.com.

 

Contact Information

 

 

Current Management

  • Patricia Scheller / CEO
    • Patricia s commitment to the healthcare industry spans more than years. Prior to joining Viveve, she served as the CEO of Prescient Medical, Inc. PMI , a privately held company that developed diagnostic imaging catheters and coronary stents designed to reduce deaths from heart attacks. Before PMI she was the CEO of SomaLogic, a molecular diagnostic company dedicated to developing protein signature arrays. Patricia also managed several business units at OrthoClinical Diagnostics, a Johnson amp Johnson company, and served in key executive positions at Dade Behring, a clinical diagnostics firm. In addition, she was director of cardiology systems at Cordis, a Johnson amp Johnson company renowned for pioneering vascular disease treatments. There, she was responsible for launching the PALMAZSCHATZ balloonexpandable stent, the first stent to achieve over a billion dollars in sales. Patricia received a B.S.E. degree in Biomedical Engineering from Duke University and completed executive business education programs at Harvard University, Massachusetts Institute of Technology, Columbia University and Northwestern University.
  • Scott Durbin / CFO
    • Scott joined Viveve as Chief Financial Officer in January . His year career in corporate finance and strategy for the life science industry brings a wealth of finance experience to our organization. Prior to joining Viveve, he was Chief Financial Officer of Aastrom Biosciences, a publicly traded, cardiovascular cell therapy company. Before Aastrom, he spent six years as Chief Operating and Financial Officer for Prescient Medical,Inc. PMI , a privately held company that developed diagnostic imaging catheters and coronary stents designed to reduce deaths from heart attacks. Prior to PMI, he spent several years as a financial consultant for two publicly traded biotech companies, Scios, Inc. a Johnson amp Johnson company and Alteon, Inc. He began his career in corporate finance as an investment banker in the healthcare and M amp A groups at Lehman Brothers Inc., where he focused on mergers and acquisitions and financings for the life science industry. At Lehman, he successfully executed over billion in transactions for medical device and biotech companies. He began his career as a Director of Neurophysiology for Biotronic, Inc. Scott received a B.S. from the University of Michigan and an M.P.H. in Health Management with Honors from the Yale University School of Medicine and School of Management.
  • James Atkinson / CBO, President
    • James Atkinson has over years of experience in medical device sales, marketing and business development with both Fortune and startup device companies. He joined Viveve as Chief Business Officer and President in February, . Prior to joining Viveve, Mr. Atkinson was a principal at Ulthera, Inc. from October, through April, , where he served as Senior Vice President of Sales and Marketing and Senior Vice President of Global Sales. Before joining Ulthera, Mr. Atkinson served as Vice President of Sales and Marketing for the Cardiac Surgery Division at St. Jude Medical, Inc. where his responsibilities included launching the Biocor stented tissue valve, recognized as the fastest growing heart valve brand in the industry. Prior to St. Jude Medical, he served as Vice President of Sales for Medtronic Vascular, a million division of Medtronic, Inc. Mr. Atkinson s entrepreneurial spirit led him to cofound and serve as Vice President of Sales and Business Development for Medical Simulation Corporation, the leading developer of stateoftheart simulation technologies and services for the cardiology, cardiac surgery and nursing industries. His career began as a sales representative at Ethicon Endosurgery, a Johnson and Johnson company, where he progressed through positions of increasing responsibility to Regional Manager.
  • Brigitte Smith / Chairman, Independent Director
    • Brigitte Smith has twenty years of experience in venture capital, business strategy and startup company operations. Brigitte has been investing and managing investments for GBS s Ventures million of life science specialized venture capital funds since . Brigitte is on the board of AirXpanders, Inc., Neuromonics Pty Ltd, Proacta, Inc. and Viveve, Inc., all of which are GBS Ventures portfolio companies. Brigitte was the founding investor and chair of Pharmaxis Pty Ltd. Prior to founding GBS Ventures, Brigitte worked in the US and Australia in operating roles with early stage technology based companies, and at Bain amp Company as a strategic management consultant. Brigitte has received a B. Chem Eng Honours from the University of Melbourne, and as a Fulbright Scholar completed a MBA Honours from the Harvard Business School and a MALD from the Fletcher School of Law and Diplomacy, both in Boston, Massachusetts. Brigitte has also been an adjunct lecturer in Entrepreneurial Finance at Melbourne Business School.
  • Mark S Colella / Independent Director
    • Mark S. Colella has over years of venture capital and operating experience in life science, medical device and healthcare companies.Mr. Colella is a Partner at Stamos Capital Partners and leads the private capital investment team. Previously a Principal, Mr. Colella is now an Advisor to AM Ventures where he has held board and advisory roles with a number of public and private companies. Mr. Colella was an executive for B RRX Medical, a medical device company sold to Covidien for million, and he held management roles with Stryker, a medical device company focused on orthopedics, laparoscopy, urology, gynecology, and minimally invasive general surgery. He spent four years as an Executive Director managing healthcare facilities with Primrose Alzheimer s Living, an earlystage healthcare service startup company, and one year working as an analyst for Versant Ventures, a life science venture capital firm. Mr. Colella holds a B.S. in Biology from Williams College and earned his M.B.A. from Northwestern University, the Kellogg School of Management, where he sits on the Advisory Board for the Innovation and New Ventures Office. Prior to Williams College, he spent two years at the United States Air Force Academy.
  • Daniel Janney / Independent Director
    • Dan joined Alta immediately following the firm s founding in , and was a cofounder of the Alta BioPharma effort. Dan focuses on investments in biopharmaceutical products and therapeutics. He has been directly involved in the funding and development of over life sciences companies. Dan is currently on the board of directors of a number of companies, including Alba Therapeutics, Esperion Therapeutics, Neothetics, Prolacta Bioscience and ViroBay. In addition, he led Alta s investments in ChemGenex Pharmaceuticals, CoTherix, Definity Health, DiscoveRx, Dynavax, Endonetics, Ilex Oncology, InterMune, LJL Biosystems and Mako Surgical. Prior to joining Alta, he was a senior investment banker at Montgomery Securities, focusing on life sciences companies. Dan is also a member of The President s Council of the Gladstone Institutes. He holds a B.A. in History from Georgetown University and a M.B.A. from the Anderson School at the University of California, Los Angeles.
  • Jon M. Plexico / Independent Director
    • Mr. Plexico was appointed tot he board as a representative of Stonepine, at Stonepine s election, under the terms of that certain letter agreement, dated May , the Letter Agreement , by and between the Company and Stonepine, pursuant to which, among other things, for so long as Stonepine owns at least of the Company s outstanding equity securities, Stonepine shall have the option, but not the obligation, to designate a Stonepine representative to serve on the Board, subject to and in accordance with the Company s charter and organizational documents and the Yukon Business Corporations Act. Pursuant to paragraph of Appendix to the Company s Articles of Continuance, as amended, and the Company s ByLaws, the directors of the Company may, between annual meetings of the Company, appoint one or more additional directors to serve until the next annual meeting but the number of additional directors shall not at any time exceed one third of the number of directors who held office at the expiration of the last annual meeting. Mr. Plexico has not been appointed to any Board committees.
  • Patricia Scheller / Director
    • Patricia s commitment to the healthcare industry spans more than years. Prior to joining Viveve, she served as the CEO of Prescient Medical, Inc. PMI , a privately held company that developed diagnostic imaging catheters and coronary stents designed to reduce deaths from heart attacks. Before PMI she was the CEO of SomaLogic, a molecular diagnostic company dedicated to developing protein signature arrays. Patricia also managed several business units at OrthoClinical Diagnostics, a Johnson amp Johnson company, and served in key executive positions at Dade Behring, a clinical diagnostics firm. In addition, she was director of cardiology systems at Cordis, a Johnson amp Johnson company renowned for pioneering vascular disease treatments. There, she was responsible for launching the PALMAZSCHATZ balloonexpandable stent, the first stent to achieve over a billion dollars in sales. Patricia received a B.S.E. degree in Biomedical Engineering from Duke University and completed executive business education programs at Harvard University, Massachusetts Institute of Technology, Columbia University and Northwestern University.
  • Carl Simpson / Independent Director
    • Carl has worked in the medical/medical device arena for over years. His undergraduate training is in Microbiology and Biochemistry. His graduate degree is in Electrical Engineering/Computer Science and he holds an MBA, both from the University of Santa Clara. After graduate school and a short period working for HewlettPackard s medical business group, Carl began an unanticipated excursion into medical device entrepreneurship. With John Simpson, M.D., Ph.D., and Ray Williams, Advanced Cardiovascular Systems ACS was formed and was Carl s first entrepreneurial effort. The company was sold to Lilly in and spunoff into Guidant in . Recently, Guidant was sold to Boston Scientific and Abbott Vascular. For Carl, ACS created the experience, motivation, and entrepreneurial drive to launch into a career of working with other entrepreneurs in establishing over medical device companies. He has been on the board of multiple medical device companies. Carl worked with Versant Ventures for four years learning the VC business and assisting them in defining new companies for future investments.

Current Share Structure

  • Market Cap: $59,724,531 - 05/18/2018
  • Authorized: 75,000,000 - 05/01/2018
  • Issue and Outstanding: 31,269,388 - 05/01/2018
  • Float: 3,780,908 - 04/15/2016

 


Recent Filings from (NASDAQ: VIVE)

Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: August, 23 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: August, 23 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: August, 09 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: August, 09 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: July, 13 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: July, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: June, 18 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: June, 11 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: June, 05 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 29 2018

 

 


Daily Technical Chart for (NASDAQ: VIVE)

Daily Technical Chart for (NASDAQ: VIVE)


Stay tuned for daily updates and more on (NASDAQ: VIVE)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: VIVE)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in VIVE is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of VIVE and does not buy, sell, or trade any shares of VIVE. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/